Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

October 22, 2024 M&A

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.

The new shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 22 October 2024. Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's shares are listed on Nasdaq Stockholm.

Vinge’s team consisted primarily of Rikard Lindahl, Joel Magnusson, Annie Fällström and Carl Lexenberg.

Related

Vinge is advising Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.
December 03, 2024

Vinge has represented Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB

Vinge has represented the leading infrastructure group Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB from Vestum. These companies are engaged in contracting activities within the construction sector. The total purchase price for the shares amounts to 747 MSEK. All key executives in the companies will become shareholders in Eleda.
December 02, 2024

Vinge has advised Fortum in connection with the divestment of its recycling and waste business

Vinge, alongside among others Castrén & Snellman, has advised Fortum in connection with the divestment of its recycling and waste business to Summa Equity through its portfolio company NG Group. The debt free purchase price is approximately EUR 800 million.
December 02, 2024